Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple ...

Biogen (NASDAQ:BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense oligonucleotide therapy targeting tau for Alzheimer’s disease treatment. In ...

Biogen recently received Fast Track designation from the FDA for its Alzheimer's therapy, BIIB080, signaling a significant advancement in its drug development ambitions. However, despite these ...

14 analysts have shared their evaluations of Biogen BIIB during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...

The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Biogen has a 1 year low of $122.77 and a 1 year high of $238.00. The firm has a market cap of $18.00 billion, a PE ratio of 10.99, a price-to-earnings-growth ratio of 1.51 and a beta of 0.01.

April 15 (Reuters) - The European Commission on Tuesday authorized the use of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab drug to treat some patients with mild cognitive ...

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an ...

Ready, set, glam. Whether snapping selfies or hitting the red carpet, stars often owe their airbrushed makeup looks to quality setting powders. Keep scrolling to explore (and shop) the pressed ...

The FDA has granted Fast Track designation to Biogen’s BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau for the treatment of Alzheimer disease (AD). In a press release ...

The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080 ...